Omnicell (OMCL) is Reiterated by FBR Capital to Outperform, Raises Price Target to $ 40

Omnicell (OMCL) was Reiterated by FBR Capital to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 40 from a previous price target of $35 . FBR Capital advised their investors in a research report released on Jul 7, 2016.

On the company’s financial health, Omnicell reported $0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.26. The company had revenue of $171.00 million for the quarter, compared to analysts expectations of $167.17 million. The company’s revenue was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.

Omnicell closed down -0.59 points or -1.65% at $35.14 with 1,81,722 shares getting traded on Tuesday. Post opening the session at $35.73, the shares hit an intraday low of $35 and an intraday high of $36.11 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

In a different news, on Jul 1, 2016, Robin Gene Seim (EVP, Global A & M Adherence) sold 3,645 shares at $35.00 per share price. According to the SEC, on Jun 6, 2016, Jorge R. Taborga (Executive VP. Engineering) sold 25,979 shares at $33.00 per share price. On May 25, 2016, Gary S Petersmeyer (director) sold 6,250 shares at $31.22 per share price, according to the Form-4 filing with the securities and exchange commission.

Omnicell Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company has two operating segments: Automation and Analytics and Medication Adherence. The Automation and Analytics segment is organized around the design manufacturing selling and servicing of medication and supply dispensing systems pharmacy inventory management systems and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards packaging equipment and ancillary products and services. The Company’s products include OmniRx SinglePointe AnywhereRN OptiFlex MS OptiFlex CL AccuFlex Autobond AutoGen and SureSeal among others.


Leave a Reply

Omnicell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omnicell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.